Paraoxonase and arylesterase activity in bladder cancer;Mesane kanserinde paraoksanaz ve arilesteraz aktivitesi

Turk Uroloji Dergisi

Volumn 43, Issue 2, 2017, Pages 147-151

  Utanğaç, Mehmet Mazhar ^a   Yeni, Ercan ^b   Savaş, Murat ^c   Altunkol, Adem ^c   Çiftçi, Halil ^b   Gümüş, Kemal ^b   Demir, Mehmet ^b  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c MINISTRY OF HEALTH   (Turkey)

Author keywords

Antioxidant; Arylesterase; Bladder cancer; Paraoxonase

Indexed keywords

EID: 85020215633     PISSN: 13005804     EISSN: 13084631     Source Type: Journal    
DOI: 10.5152/tud.2017.89411     Document Type: Article

References (32)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. [CrossRef]
2. Washio M, Mori M, Mikami K, Miki T, Watanabe Y, Nakao M, et al. Risk Factors for Upper and Lower Urinary Tract Cancer Death in a Japanese Population: Findings from the Japan Collaborative Cohort Study for Evaluation of Cancer Risk JACC Study. Asian Pac J Cancer Prev 2016;17:3545-9.
3. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6. [CrossRef]
4. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334-6. [CrossRef]
5. Altan N, Sepici Dinçel A, Koca C. Diabetes mellitus and oxidative stress. Turk J Biochem 2006;31:51-6.
6. Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochem Funct 2006;24:455-60. [CrossRef]
7. Manoharan S, Baskar AA, Manivasagam T, Subramanian P. Circadian rhythmicity of plasma lipid peroxidation and antioxidants in oral squa-mous cell carcinoma. Singapore Med J 2005;46:184-8
8. Kurban S, Akpınar Z, Mehmetoğlu İ. Investigation of serum paraoxonase and arylesterase activities and oxidative stress in patients with multiple sclerosis. Genel Tıp Derg 2010;20:13-7.
9. Aviram M, Rosenblat M, Bisgair CL. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions: a possible peroxida-tive role for paraoxonase. J Clin Invest 1998;101:1581-90. [CrossRef]
10. Mackness MI, Mackness B, Durington PN, Connely PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipopro-teins. Curr Opin Lipidol 1996;7:69-76. [CrossRef]
11. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraox-onase-1. Clin Sci 2004;107:435-47. [CrossRef]
12. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4. [CrossRef]
13. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS radical cation. Clin Biochem 2004;37:277-85. [CrossRef]
14. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11. [CrossRef]
15. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 2003;133:563-6.
16. Amasyali AS, Kucukgergin C, Erdem S, Sanli O, Seckin S, Nane I. Nitric Oxide Synthase [eNOS4a/b] Gene Polymorphism is Associated with Tumor Recurrence and Progression in Superficial Bladder Cancer Cases. J Urol 2012;188:2398-403. [CrossRef]
17. Patchsung M, Boonla C, Amnattrakul P, Dissayabutra T, Mutirangura A, Tosukhowong P. Long interspersed nuclear element-1 hypometh-ylation and oxidative stress: correlation and bladder cancer diagnostic potential. PLoS One 2012;7:e37009. [CrossRef]
18. Aydin O, Yalcinkaya S, Eren E, Ergin M, Eroglu M, Yilmaz N. Diminished arylesterase enzyme activity and total thiol levels in bladder cancer patients. Clin Lab 2013;59:1231-7. [CrossRef]
19. Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O, Sezer C. Enhanced HDL-cholesterol-associated antioxidant PON-1 activity in prostate cancer patients. Kaohsiung J Med Sci 2013;29:368-73. [CrossRef]
20. Bulbuller N, Eren E, Ellidag HY, Oner OZ, Sezer C, Aydin O, et al. Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. Neoplasma 2013;60:419-24. [CrossRef]
21. Arioz DT, Camuzcuoglu H, Toy H, Kurt S, Celik H, Erel O. Assessment of serum paraoxonase and arylesterase activity in patients with endome-trial cancer. Eur J Gynaecol Oncol 2009;30:679-82.
22. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50:273-5.
23. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50:225-7.
24. Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 2009;112:481-5. [CrossRef]
25. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48. [CrossRef]
26. Gecit I, Aslan M, Gunes M, Pirincci N, Esen R, Demir H, et al. Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 2012;138:739-43. [CrossRef]
27. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9. [CrossRef]
28. Badjatia N, Satyam A, Singh P, Seth A, Sharma A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 2010;28:360-7. [CrossRef]
29. Halliwell B. Reactive oxygen species in living system: source, biochemistry and role in human disease. Am J Med 1991;91:14-21. [CrossRef]
30. Balci H, Genc H, Papila C, Can G, Papila B, Yanardag H, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin LabAnal 2012;26:155-60. [CrossRef]
31. Oztürk O, Kağnici OF, Oztürk T, Durak H, Tüzüner BM, Kisakesen HI, et al. 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res 2009;29:4041-6.
32. Comstock GW, Alberg AJ, Huang HY, Wu K, Burke AE, Hoffman SC, et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acids, carotenoids, alpha-tocopherol, selenium and total peroxyl radical absorbing capasity. Cancer Epidemiology, Biomarkers Preventions 1997;6:907-16.